Tetra Bio Pharma
Tetra Bio-Pharma Launches Medical Marijuana Trials to Prove Efficacy & Safety of Therapeutic Cannabis as Global Medical Marijuana Market Predicted to Hit US$55.8 Billion by 2025
Tetra Bio-Pharma Chief Science Officer Dr. Guy Chamberland “The bottom line is that they want good science.” Andre Rancourt, Ryan Brown and Dr. Guy Chamberland are very excited over the future prospects for Tetra Bio-Pharma, (CSE: TBP) (OTCQB: GRPOF). Brown is the company’s Vice-President of Business Development, Chamberland is its Chief Science Officer and Rancourt is the CEO. “The company has a very different model,” says Dr. Chamberland. “I tell people now that we are trading three times undervalue,” says Brown. Tetra is in the business of developing cannabis based prescription drugs.
- REPORT PUBLISHED 2017
- CATEGORY Cannabis-based Pharmaceuticals
Deep South Resources
On February 14, 2017, junior mining company Deep-South Resources Inc., (TSX-V: DSM) received a Valentine’s Day card from Canadian securities regulator IIROC announcing that it had halted its stock from trading due to pending material changes. The material changes meant that Deep-South was going to add Teck’s 70{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} in the Haib Copper Deposit to the 30{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} it already owned giving it a 100{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} interest in the largest known copper porphyry deposit in Africa. IIROC lifted the trading halt on February 23, 2017.
- REPORT PUBLISHED 2017
- CATEGORY Mining